Cargando…

Current management of RET rearranged non-small cell lung cancer

The identification of oncogenic drivers, and the subsequent development of targeted therapies established biomarker-based care for metastatic non-small cell lung cancer (NSCLC). Biomarker testing is standard of care in NSCLC patients with adenocarcinoma because multiple targeted therapies are availa...

Descripción completa

Detalles Bibliográficos
Autor principal:	Stinchcombe, Thomas E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385825/ https://www.ncbi.nlm.nih.gov/pubmed/32782485 http://dx.doi.org/10.1177/1758835920928634

Ejemplares similares

Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
por: Mendoza, Luis
Publicado: (2018)

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Therapeutic strategies in RET gene rearranged non-small cell lung cancer
por: Drusbosky, Leylah M., et al.
Publicado: (2021)

Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions
por: Ackermann, Christoph Jakob, et al.
Publicado: (2019)

Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements
por: Digumarthy, Subba R., et al.
Publicado: (2020)

Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial
por: Stinchcombe, Thomas E.
Publicado: (2023)

Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)
por: Takeuchi, Shinji, et al.
Publicado: (2021)

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement
por: Zhou, Ning, et al.
Publicado: (2022)

RET Inhibitors in Non-Small-Cell Lung Cancer
por: Cascetta, Priscilla, et al.
Publicado: (2021)

RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
por: Tsuta, K, et al.
Publicado: (2014)

Non-small-cell lung cancer: how to manage RET-positive disease
por: Andrini, Elisa, et al.
Publicado: (2022)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Comparison of Rearranged During Transfection (RET) Gene Rearrangements in Primary Versus Metastatic Non-Small Cell Lung Cancer (NSCLC)
por: Zhang, Quxia, et al.
Publicado: (2018)

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
por: Jeon, Youngkyung, et al.
Publicado: (2023)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
por: Takeda, Masayuki, et al.
Publicado: (2019)

Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients
por: Feng, Junnan, et al.
Publicado: (2022)

Recent advances in the treatment of non-small cell and small cell lung cancer
por: Stinchcombe, Thomas E.
Publicado: (2014)

1p/19q codeletion and RET rearrangements in small-cell lung cancer
por: Lu, Hongyang, et al.
Publicado: (2016)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
por: Offin, Michael, et al.
Publicado: (2019)

On the RET Rearrangements in Chernobyl-Related Thyroid Cancer
por: Jargin, Sergei V.
Publicado: (2012)

Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
por: Stinchcombe, Thomas E
Publicado: (2007)

RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer
por: Sasaki, Hidefumi, et al.
Publicado: (2012)

The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
por: Ke, Jun-yi, et al.
Publicado: (2023)

Decade in review: a new era for RET-rearranged lung cancers
por: Choudhury, Noura J., et al.
Publicado: (2020)

RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature
por: Baglivo, Sara, et al.
Publicado: (2020)

Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China
por: Li, Tao, et al.
Publicado: (2023)

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes
por: Rocco, Danilo, et al.
Publicado: (2023)

RET rearrangements are actionable alterations in breast cancer
por: Paratala, Bhavna S., et al.
Publicado: (2018)

Narrative review: blood and tumor biomarker testing in non-small cell lung cancer without an oncogenic driver
por: Stinchcombe, Thomas E.
Publicado: (2023)

Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
por: Rossi, Giulio, et al.
Publicado: (2017)

RET Fusion Genes in Korean Non-Small Cell Lung Cancer
por: Yoo, Seung Soo, et al.
Publicado: (2013)

Research Progress on RET Fusion in Non-Small-Cell Lung Cancer
por: Zhao, Lu, et al.
Publicado: (2022)

Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients
por: Zhang, Kai, et al.
Publicado: (2019)

Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study
por: Lu, Chang, et al.
Publicado: (2020)

The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients
por: Fu, Sha, et al.
Publicado: (2015)

Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer
por: Rogers, Toni-Maree, et al.
Publicado: (2017)

Targeted therapy of RET fusion-positive non-small cell lung cancer
por: Shen, Zixiong, et al.
Publicado: (2022)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer
por: O’Leary, Connor, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bi35de22teqbbu2i745mcvj3jb